These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8701811)

  • 21. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.
    Crew JP; O'Brien T; Bradburn M; Fuggle S; Bicknell R; Cranston D; Harris AL
    Cancer Res; 1997 Dec; 57(23):5281-5. PubMed ID: 9393750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
    Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
    Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
    Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
    Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bladder carcinoma: understanding advanced and metastatic disease with potential molecular therapeutic targets.
    Ahmed HU; Arya M; Patel HR
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):1011-22. PubMed ID: 16336092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
    Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
    Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relation between p53 overexpression and lymph node metastases in clinical stage t2 and t3a transitional cell bladder carcinoma.
    Uygur MC; Yaman I; Kutluay L; Altuğ U; Erol D
    J Exp Clin Cancer Res; 1999 Sep; 18(3):391-5. PubMed ID: 10606186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of high-risk, non-muscle-invasive bladder cancer.
    Lerner SP
    Nat Clin Pract Urol; 2006 Aug; 3(8):398-9. PubMed ID: 16902498
    [No Abstract]   [Full Text] [Related]  

  • 28. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
    Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
    Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
    Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
    Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer.
    Tran E; Souhami L; Tanguay S; Rajan R
    Am J Clin Oncol; 2009 Aug; 32(4):333-7. PubMed ID: 19381080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
    Dhawan D; Ramos-Vara JA; Stewart JC; Zheng R; Knapp DW
    Urol Oncol; 2009; 27(3):284-92. PubMed ID: 18562222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder.
    Hussain SA; Ganesan R; Hiller L; Cooke PW; Murray P; Young LS; James ND
    Oncol Rep; 2003; 10(3):571-6. PubMed ID: 12684626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bladder cancer.
    Ozen H
    Curr Opin Oncol; 1998 May; 10(3):273-8. PubMed ID: 9619365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.
    Pagliaro LC; Keyhani A; Williams D; Woods D; Liu B; Perrotte P; Slaton JW; Merritt JA; Grossman HB; Dinney CP
    J Clin Oncol; 2003 Jun; 21(12):2247-53. PubMed ID: 12805322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
    Dekairelle AF; Tombal B; Cosyns JP; Gala JL
    Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
    Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Urothelial cancers. Cytogenetic and molecular biology principles].
    Strohmeyer T
    Urologe A; 1994 Mar; 33(2):122-7. PubMed ID: 7909968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bladder preserving approach for muscle invasive bladder cancer--role of mycobacterium w.
    Chaudhuri P; Mukhopadhyay S
    J Indian Med Assoc; 2003 Sep; 101(9):559-60. PubMed ID: 15168998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Editorial comment on: Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker.
    Shariat SF
    Eur Urol; 2009 Oct; 56(4):688-9. PubMed ID: 18513852
    [No Abstract]   [Full Text] [Related]  

  • 40. Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumor suppressor genes, and growth factors.
    Sidransky D; Messing E
    Urol Clin North Am; 1992 Nov; 19(4):629-39. PubMed ID: 1441021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.